PHP
AKRO

Parkman Healthcare Partners’s Akero Therapeutics AKRO Stock Holding History

Parkman Healthcare Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-116,107
Closed -$5.87M – 92
2023
Q3 		$5.87M Buy
116,107
+81,107
+232% +$3.78M 1.08% 30
2023
Q2 		$1.63M Buy
+35,000
New +$1.6M 0.28% 81
2020
Q3 		– Sell
-95,000
Closed -$2.37M – 85
2020
Q2 		$2.37M Buy
+95,000
New +$2.17M 0.67% 51

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parkman Healthcare Partners's AKRO Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 116,107 shares — an estimated $5.87M sold.

Parkman Healthcare Partners first reported a position in AKRO in Q2 2020 and held it in 3 quarters. The position peaked at $5.87M in Q3 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • Parkman Healthcare Partners reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 116,107 Akero Therapeutics shares in Q4 2023, an estimated $5.87M.
  • Parkman Healthcare Partners first reported a position in Akero Therapeutics in Q2 2020 and held it in 3 quarters.
  • Parkman Healthcare Partners's Akero Therapeutics position peaked at $5.87M in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.